Cymabay Therapeutics
CBAY
CBAY was delisted on the 21st of March, 2024.
117 hedge funds and large institutions have $396M invested in Cymabay Therapeutics in 2022 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 29 increasing their positions, 29 reducing their positions, and 7 closing their positions.
271% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 7
86% more call options, than puts
Call options by funds: $2.79M | Put options by funds: $1.5M
82% more capital invested
Capital invested by funds: $218M → $396M (+$178M)
17% more funds holding
Funds holding: 100 → 117 (+17)
0% more funds holding in top 10
Funds holding in top 10: 6 → 6 (0)
0% more repeat investments, than reductions
Existing positions increased: 29 | Existing positions reduced: 29
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OCA
Octagon Capital Advisors
New York
|
+$7.07M |
| 2 |
LGM
Logos Global Management
San Francisco,
California
|
+$4.75M |
| 3 |
Janus Henderson Group
London,
|
+$4.73M |
| 4 |
ACP
Acuta Capital Partners
Redwood City,
California
|
+$3.86M |
| 5 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$2.85M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
-$5.82M |
| 2 |
ACM
Altium Capital Management
New York
|
-$2.76M |
| 3 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$2.56M |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$2.39M |
| 5 |
Millennium Management
New York
|
-$2.29M |
CBAY Hedge Fund Activity: Q4 2022 in Review
117 of the 6,237 institutional investors tracked by Wall St. Rank reported a position in Cymabay Therapeutics (CBAY) for Q4 2022, worth a combined $396M — up 82% from $218M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new CBAY positions and 7 closed out — a net gain of 19 holders — while 29 added to existing stakes and 29 trimmed.
The largest buyer was Octagon Capital Advisors, opening a new position worth an estimated $7.07M. The largest seller was DAFNA Capital Management, cutting an estimated $5.82M.
- 117 institutional investors held Cymabay Therapeutics (CBAY) as of Q4 2022, up from 100 in Q3 2022.
- Funds reported $396M of Cymabay Therapeutics stock for Q4 2022, up 82% quarter-over-quarter.
- 26 funds opened new Cymabay Therapeutics positions in Q4 2022 and 7 closed out, a net change of +19 holders.
- The largest Cymabay Therapeutics buyer in Q4 2022 was Octagon Capital Advisors, an estimated $7.07M added.
- The largest Cymabay Therapeutics seller in Q4 2022 was DAFNA Capital Management, an estimated $5.82M sold.
Based on aggregated 13F filings for Q4 2022.